Eur Rev Med Pharmacol Sci 2019; 23 (4 Suppl): 5-13

DOI: 10.26355/eurrev_201911_19378

Tapentadol prolonged release in the treatment of musculoskeletal pain: an innovative pharmacological option

F. Marinangeli, M. Evangelista, G. Finco

Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy. francomarinangeli@gmail


Musculoskeletal pain, encompassing back and osteoarthritis (OA) pain, represents the most frequent source of chronic pain in western countries, and it is particularly frequent in older adults. Remarkably, back and OA pain present, in most cases, both a nociceptive and a neuropathic component of pain. Treatment selection should, therefore, properly consider the ability of a drug to act on both components, reducing the possibility of plastic changes in the central nervous system, and consequently promoting physical rehabilitation.
The pharmacological profile of tapentadol, combining synergistically µ-opioid receptor (MOR) agonist and norepinephrine reuptake inhibition (NRI) in one single molecule with a concomitant reduction in the burden of adverse events, is unique, to date, and makes this drug particularly suitable for the treatment of back pain and OA-associated pain, especially when a neuropathic component is present.
Tapentadol is an innovative dual-acting analgesic molecule, which combines two mechanisms of action, namely MOR agonism and NRI. This narrative review will briefly discuss the pharmacological action of tapentadol and its rationale for use in back pain and OA.

Free PDF Download

To cite this article

F. Marinangeli, M. Evangelista, G. Finco
Tapentadol prolonged release in the treatment of musculoskeletal pain: an innovative pharmacological option

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 4 Suppl
Pages: 5-13
DOI: 10.26355/eurrev_201911_19378